479 related articles for article (PubMed ID: 36444790)
1. Novel pyrazole-based COX-2 inhibitors as potential anticancer agents: Design, synthesis, cytotoxic effect against resistant cancer cells, cell cycle arrest, apoptosis induction and dual EGFR/Topo-1 inhibition.
Halim PA; Sharkawi SMZ; Labib MB
Bioorg Chem; 2023 Feb; 131():106273. PubMed ID: 36444790
[TBL] [Abstract][Full Text] [Related]
2. Characterization of novel heterocyclic compounds based on 4-aryl-4H-chromene scaffold as anticancer agents: Design, synthesis, antiprofilerative activity against resistant cancer cells, dual β-tubulin/c-Src inhibition, cell cycle arrest and apoptosis induction.
Abdelall EKA; A H Elshemy H; Labib MB; E A Mohamed F
Bioorg Chem; 2022 Mar; 120():105591. PubMed ID: 34998122
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis of novel chromene-based scaffolds targeting hepatocellular carcinoma: Cell cycle arrest, cytotoxic effect against resistant cancer cells, apoptosis induction, and c-Src inhibition.
Abdelall EKA; Elshemy HAH; Labib MB; Mohamed FEA
Drug Dev Res; 2024 Feb; 85(1):e22133. PubMed ID: 37971069
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, modeling studies and biological evaluation of pyrazole derivatives linked to oxime and nitrate moieties as nitric oxide donor selective COX-2 and aromatase inhibitors with dual anti-inflammatory and anti-neoplastic activities.
A A Fadaly W; A M M Elshaier Y; T M Nemr M; R A Abdellatif K
Bioorg Chem; 2023 May; 134():106428. PubMed ID: 36893546
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and molecular docking study of new pyrimidine-based hydrazones with selective anti-proliferative activity against MCF-7 and MDA-MB-231 human breast cancer cell lines.
Badawi WA; Samir M; Fathy HM; Okda TM; Noureldin MH; Atwa GMK; AboulWafa OM
Bioorg Chem; 2023 Sep; 138():106610. PubMed ID: 37210828
[TBL] [Abstract][Full Text] [Related]
6. Annulated pyrazole derivatives as a novel class of urokinase (uPA) inhibitors: Green synthesis, anticancer activity, DNA-damage evaluation, and molecular modelling study.
Farag PS; AboulMagd AM; Hemdan MM; Hassaballah AI
Bioorg Chem; 2023 Jan; 130():106231. PubMed ID: 36335649
[TBL] [Abstract][Full Text] [Related]
7. New pyranopyrazole based derivatives: Design, synthesis, and biological evaluation as potential topoisomerase II inhibitors, apoptotic inducers, and antiproliferative agents.
Sobh EA; Kassab AE; El-Khouly EA; S A Hassan M
Bioorg Chem; 2024 Mar; 144():107158. PubMed ID: 38301427
[TBL] [Abstract][Full Text] [Related]
8. Novel Pyrimidine-5-Carbonitriles as potential apoptotic and antiproliferative agents by dual inhibition of EGFR
Reda N; Mohamed KO; Abdou K; Helwa AA; Elshewy A
Bioorg Chem; 2024 Apr; 145():107185. PubMed ID: 38350273
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and molecular docking of novel pyrazole-chalcone analogs of lonazolac as 5-LOX, iNOS and tubulin polymerization inhibitors with potential anticancer and anti-inflammatory activities.
Ahmed AHH; Mohamed MFA; Allam RM; Nafady A; Mohamed SK; Gouda AE; Beshr EAM
Bioorg Chem; 2022 Dec; 129():106171. PubMed ID: 36166898
[TBL] [Abstract][Full Text] [Related]
10. New benzothienopyrimidine derivatives as dual EGFR/ARO inhibitors: Design, synthesis, and their cytotoxic effect on MCF-7 breast cancer cell line.
Sobh EA; Khalil NA; Faggal SI; Hassan MSA
Drug Dev Res; 2022 Aug; 83(5):1075-1096. PubMed ID: 35286757
[TBL] [Abstract][Full Text] [Related]
11. New pyrrolidine-carboxamide derivatives as dual antiproliferative EGFR/CDK2 inhibitors.
Frejat FOA; Zhao B; Furaijit N; Wang L; Abou-Zied HA; Fathy HM; Mohamed FAM; Youssif BGM; Wu C
Chem Biol Drug Des; 2024 Jan; 103(1):e14422. PubMed ID: 38230772
[TBL] [Abstract][Full Text] [Related]
12. A novel class of pyrazole analogues as aurora kinase A inhibitor: design, synthesis, and anticancer evaluation.
Yevale DB; Teraiya N; Lalwani TD; Ameta RK; Sangani CB
Bioorg Chem; 2023 Dec; 141():106901. PubMed ID: 37797455
[TBL] [Abstract][Full Text] [Related]
13. Novel 1,3-diaryl pyrazole derivatives bearing methylsulfonyl moiety: Design, synthesis, molecular docking and dynamics, with dual activities as anti-inflammatory and anticancer agents through selectively targeting COX-2.
Shaker AMM; Shahin MI; AboulMagd AM; Abdel Aleem SA; Abdel-Rahman HM; Abou El Ella DA
Bioorg Chem; 2022 Dec; 129():106143. PubMed ID: 36191430
[TBL] [Abstract][Full Text] [Related]
14. Discovery and optimization of 2,3-diaryl-1,3-thiazolidin-4-one-based derivatives as potent and selective cytotoxic agents with anti-inflammatory activity.
Shawky AM; Almalki FA; Abdalla AN; Youssif BGM; Abdel-Fattah MM; Hersi F; El-Sherief HAM; Ibrahim NA; Gouda AM
Eur J Med Chem; 2023 Nov; 259():115712. PubMed ID: 37567059
[TBL] [Abstract][Full Text] [Related]
15. Benzoxazole-appended piperidine derivatives as novel anticancer candidates against breast cancer.
AboulWafa OM; Daabees HMG; El-Said AH
Bioorg Chem; 2023 May; 134():106437. PubMed ID: 36842320
[TBL] [Abstract][Full Text] [Related]
16. Multi-target rational design and synthesis of novel diphenyl-tethered pyrazolopyrimidines targeting EGFR and topoisomerase II with potential DNA intercalation and apoptosis induction.
Gaber AA; Abo Elmaaty A; Sharaky M; Mosa AA; Yahya Abdullah Alzahrani A; Shaaban S; Eldehna WM; Al-Karmalawy AA
Bioorg Chem; 2024 Apr; 145():107223. PubMed ID: 38387399
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and antitumor screening of new thiazole, thiazolopyrimidine, and thiazolotriazine derivatives as potent inhibitors of VEGFR-2.
Abd Elhameed AA; Ali AR; Ghabbour HA; Bayomi SM; El-Gohary NS
Drug Dev Res; 2023 Dec; 84(8):1664-1698. PubMed ID: 37661648
[TBL] [Abstract][Full Text] [Related]
18. New Niflumic Acid Derivatives as EGFR Inhibitors: Design, Synthesis,
Yaseen YS; Mahmood AAR; Abbas AH; Shihab WA; Tahtamouni LH
Med Chem; 2023; 19(5):445-459. PubMed ID: 36537605
[TBL] [Abstract][Full Text] [Related]
19. Computational Design, Synthesis, and Bioevaluation of 2-(Pyrimidin-4-yl)oxazole-4-carboxamide Derivatives: Dual Inhibition of EGFR
Raghunath Khedkar N; Sindkhedkar M; Joseph A
Bioorg Chem; 2024 Feb; 143():107027. PubMed ID: 38096682
[TBL] [Abstract][Full Text] [Related]
20. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.
Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM
Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
